Image Ben Hargreaves Oncology Molecular glues ‘combine best attributes’ of small and large... As the industry has transitioned much of its R&D expertise into large molecule therapies, an emerging approach could provide a revolutionary treatment tool. R&D Worrying signs for trial diversity require broad industry ac... A recent report found that diversity in clinical trials has dropped. R&D AI could provide breakthrough for early diagnosis of rare di... For people living with rare diseases, one of the major challenges is being able to receive a rapid and accurate diagnosis. Market Access Big pharma is slimming down The last few years have been marked by many big pharma companies opting to move away from diversification and towards more focused operations. Load more results
Oncology Molecular glues ‘combine best attributes’ of small and large... As the industry has transitioned much of its R&D expertise into large molecule therapies, an emerging approach could provide a revolutionary treatment tool.
R&D Worrying signs for trial diversity require broad industry ac... A recent report found that diversity in clinical trials has dropped.
R&D AI could provide breakthrough for early diagnosis of rare di... For people living with rare diseases, one of the major challenges is being able to receive a rapid and accurate diagnosis.
Market Access Big pharma is slimming down The last few years have been marked by many big pharma companies opting to move away from diversification and towards more focused operations.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
